1439 - Ten-year follow-up of a phase II study of ibrutinib in relapsed/ refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)

Primary Author / Presenter(s)

AA

Aseel Alsouqi, MD

The Ohio State University
Columbus, Ohio, United States

Co-Author(s)

YH

Ying Huang

The Ohio State University
Columbus, Ohio, United States
KR

Kerry A. Rogers, MD

Associate Professor
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
SB

Seema A. Bhat, MD

Associate Professor
The Ohio State University
Columbus, Ohio, United States
MG

Michael Grever, MD

The Ohio State University
Columbus, Ohio, United States
MS

Mona Stefanos

The Ohio State University
Columbus, Ohio, United States
LF

Logan Fitzgerald

The Ohio State University
Columbus, Ohio, United States
MK

Michael Keller

The Ohio State University
Columbus, Ohio, United States
AC

Arianna Crouse

The Ohio State University
Columbus, Ohio, United States
ML

Margaret Lucas

The Ohio State University
Columbus, Ohio, United States
MM

Mollie Moran

The Ohio State University
Columbus, Ohio, United States
SH

Swetha Hinton

The Ohio State University
Columbus, Ohio, United States
CG

Cara Grantier

The Ohio State University
Columbus, Ohio, United States
CH

Corinne Hoffman

The Ohio State University
Columbus, Ohio, United States
MR

Mark Reid

The Ohio State University
Columbus, Ohio, United States
AR

Amy Ruppert

The Ohio State University
Columbus, Ohio, United States
JB

John C. C. Byrd, MD

University of Cincinnati
Cincinnati, Ohio, United States
Jennifer A. Woyach, MD

Professor of Medicine
Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
KM

Kami Maddocks, MD

The Ohio State University
Columbus, Ohio, United States